Pfizer buys Trillium and its CD47 candidates for US$2.3 billion
Interest in macrophage biology remains strong, shows Pfizer’s acquisition of Trillium Therapeutics, a company with two clinical-stage CD47-targeting candidates.
Nature Reviews Drug Discovery
Evolution of the market for mRNA technology
2020 was a breakout year for mRNA technology platforms with the launch and widespread use of mRNA vaccines for COVID-19. This article forecasts the potential of this growing market.
Nature Reviews Drug Discovery
A novel single-agent antibiotic
Antimicrobial resistance is a substantial public health challenge, and new antibiotics — especially those that target drug-resistant Gram-negative pathogens — are needed.
Nature Reviews Drug Discovery
India’s DNA COVID vaccine is a world first – more are coming
The ZyCoV-D vaccine heralds a wave of DNA vaccines for various diseases that are undergoing clinical trials around the world.
Nature
The fight to manufacture COVID vaccines in lower-income countries
Drug companies and wealthy countries are facing increased pressure to partner with firms in the global south but are reluctant to relinquish control.
Nature
Greece used AI to curb COVID: what other nations can learn
Governments are hungry to deploy big data in health emergencies and scientists must help to lay the legal, ethical and logistical groundwork. This article explores how Greece employed a machine-learning algorithm to determine which travellers entering the country should be tested for COVID-19.
Nature
Novel drug therapies could tackle treatment-resistant depression
An anesthetic, a steroid and a psychedelic are new treatments for a devastating psychiatric disorder.
Scientific American
